| Abstrakt: |
A recent report from Hanyang University in Seoul, South Korea, discusses the use of siRNA-based therapy for the treatment of brain ischemia. The researchers developed a complex consisting of a Fas-blocking peptide (FBP) and a positively charged nona-arginine peptide (9R) to deliver siRNA targeting Bax to Fas-expressing ischemic brain cells. Through intranasal administration in rat models, the complex specifically localized to the Fas-expressing infarcted region of the brain and effectively inhibited Fas signaling, reducing neuronal cell death. This targeted delivery system shows promise as an alternative treatment strategy for brain ischemia. [Extracted from the article] |
